The Biointelect management team individually have greater than 20 years’ experience and proven track records in small start-up ventures and multinational corporations.
We, therefore, uniquely understand our client’s needs. We have successfully managed business units or companies and navigated complex regulatory, clinical research, quality management, commercial, product launches and business partnering strategies.
Our consulting philosophy is to always offer a personalised and adaptable service. We take ownership of our projects seriously and strive for success as if we were part of your team.
Jennifer Herz founded Biointelect in 2011 to provide strategic commercialisation services to the biopharmaceutical industry.
Jennifer has over twenty years commercial, business development and scientific affairs experience in the biopharmaceutical industry and has held a variety of roles with responsibility for Australia, New Zealand and European markets. She was the first Managing Director of Sanofi Pasteur in Australia which was a start-up company and grew significantly over the 6 years of her tenure to be an established major provider of vaccines to the public and private market in Australia, New Zealand and the Pacific Region.
She has previously served on the Board of Medicines Australia where she led industry discussions with government related to the new funding arrangements for vaccines on the PBAC. She was also active in a variety of European and International Industry Association working groups responsible for liaison with health authorities including European Institutions and the WHO.
She is a member of the Accelerate Commercialisation Expert Network, on the Steering Committee of the NHMRC funded Centre of Research Excellence: Policy relevant infectious disease simulation and mathematical modelling (PRISM) and is a member of the Expert Reference Group of the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE).
Jennifer has extensive international & local network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors along with global experience in multiple new product launches and start-ups at all stages of development.
Karl Herz graduated from The University of Technology Sydney in Biomedicine, majoring in Biochemistry and Microbiology. He also holds a Post Graduate Certificate in Marketing.
He has over twenty-five years of varied experience in the pharmaceutical industry – from the laboratory to senior management.
Karl has extensive commercial experience (sales, marketing, business development, project management) with multinational companies, including GSK, Servier, Sanofi, Schering- Plough, Sanofi Pasteur, Sigma Pharmaceuticals and Generic Health, a subsidiary of Lupin Pharmaceuticals.
He has experience with hospitals, specialists, primary care and pharmacy channels and across a wide number of therapeutic areas ranging from OTC, generics to prescription medicines.
He is also Managing Director of Biocelect Pty Ltd which is focussed on distributing pharmaceutical and biotechnology products on behalf of companies wishing to launch their products in the Asia Pacific Region. Currently Biocelect has a prescription product progressing through the Australian Therapeutic Goods Administration, with an expected launch in the near future.
Head, Global Health Outcomes and Policy
David Grainger has forty years of experience in the pharmaceutical industry, spanning Australia, New Zealand, the United States and short assignments in Brussels and London.
He completed his life sciences studies at the University of Auckland with majors in haematology and transfusion science, management studies with the New Zealand Institute of Management and health economics at Monash University in Melbourne.
David is the co-author of numerous publications on health economics and health outcomes research.
David’s industry experience includes a range of roles in sales, marketing, health outcomes research and corporate affairs. This includes ten years as the director of corporate affairs and market access in Eli Lilly’s Australian affiliate, responsible for all health outcomes research, reimbursement dossier development & pricing functions as well as the corporate affairs functions of government relations, advocacy & communications.
More recently, David held a senior role in Lilly’s international public policy group, responsible for developing and supporting the company’s external health care policy positions related to Health Technology Assessment (HTA). David also engaged extensively with governments and thought leaders in a range of markets on policy issues related to universal health coverage, formulary management, HTA, pricing and regulatory affairs.
David has had significant involvement with industry association policy efforts and for six years chaired the HTA Task Force for PhRMA International. For five years he was a member of the Board of Directors of Health Technology Assessment International, a professional society dedicated to HTA. David is also a member of the Policy Research Advisory Committee for the Office of Health Economics in London and a casual lecturer in the Masters of Pharmaceutical Medicine program at the University of New South Wales in Sydney.
Guillaume Herry has more than ten years of international experience in the biopharmaceutical and medical device industries in the US, Europe and Australia spanning across new product development, strategic planning, business development & licensing and general management.
Guillaume holds an MBA from the Australian Graduate School of Management at University of New South Wales Business School, a Master’s Degree in Engineering for Health and Drugs (Biotechnology, Health and Management) from the University Joseph Fourier in Grenoble (France) and a Master’s Degree in Entrepreneurship in Life Sciences & Technologies from the University Paris-Sud X (France).
Guillaume has a successful track record in the design and implementation of growth strategies, innovation in healthcare across new product & service development and commercialisation, corporate and business development (acquisition, license-in, partnership) and operational and general management (including sales & marketing, full company P&L ownership).
Guillaume is also the inventor of several granted patents currently used in various commercial ventures.
Paul Dale has over seventeen years’ experience in the pharmaceutical industry including a range of roles across public policy, government relations, communications, pricing, reimbursement and sales. This includes five years in the head office of a global pharmaceutical company working on commercialisation of products in late stage development, particularly in pricing and reimbursement.
Paul has developed access and pricing strategies for multiple markets worldwide including the US, European major 5, Japan and China, resulting in successful product launches.
Paul has been involved in detailed evaluation of in-licensing and new indication commercialisation opportunities as well as alliance management.
In Australia, Paul has significantly contributed to industry committees on both medicines access and industry development policy. He has managed a team that has delivered multiple stakeholder engagement and communications campaigns across a range of disease states. Paul recently managed a team that successfully launched a new biologic asset in Australia.
Paul has a degree in public policy and has worked for a Member of Parliament.
As a Registered Nurse, Jane’s experience, knowledge and professional networks within the health sector is diverse with a significant focus on vaccines, public health programs, medical, nursing and dental recruitment, immunisation programs and private business health activities. Underpinned by a passion for public health Jane’s experience and skills drive robust strategy development and implementation in preventative health sectors.
Collaboration with all levels of Government Health Personnel (Commonwealth, State and Local) is Jane’s strength for building partnerships and developing solutions based on the needs of the day and the future. Sales and marketing experience supports all aspects of business development and integration with the Australian business sector and government.
Planning, developing and implementing health related programs, specifically immunisation related, at a national and local level is a strength from previous establishment and participation. Consolidating this with current involvement in the immunisation program implementation in the corporate, school, state and local government environment offers up to date facts and experience for new program development.
Scientific Affairs Director
Paul Cohen has 24 years’ experience in the diagnostics, biotechnology, medical device and pharmaceutical industry.
His expertise spans clinical research, regulatory affairs, pharmacovigilance, training, quality management and process re-engineering for large pharmaceutical companies, biotech and start-up ventures.
He has worked for large pharma companies including Wyeth, Merck Sharp and Dohme, Novo Nordisk, Janssen-Cilag and Roche Diagnostics; start-up ventures including Sanofi Pasteur and IBAH (the CRO now known as Omnicare) and Columna.
He has managed in excess of 20 Phase I-IV clinical and health outcome projects, both locally and globally.
His clinical research therapeutic area expertise includes vaccines and biological, anti-infectives, transplantation, antidepressants, rheumatology, oncology, diabetes, respiratory and orthopaedics. He has assisted many Australian start-up companies with their clinical research, regulatory and quality strategies and taken them from concept, through clinical phases to regulatory approval and quality certification.
He holds an ARCS Certified Fellowship in Clinical Research and is a member of ARCS, AIMS, ASM, RAPS and a Subject Matter Expert for the World Medical Device Organisation. He helped establish the Master of Health Technology Innovation (MHTI @ Sydney University/Charles Perkins Centre Course); is a lecturer in the course and is a mentor to the AusBiotech Industry Mentoring Network in STEM (IMNIS).
Paul joined Biointelect in 2016 as Director of Scientific Affairs.
Dr. Isabelle Delannoy
Dr. Isabelle Delannoy is a cross-functional Marketing Executive with thirty years experience within large multinational companies across diverse product portfolios in both Animal and Human Health.
Isabelle holds a Doctorate in Veterinary Medicine and a Master’s Degree of Management from the Business School of Paris.
Her primary interest is exploring the value of immunotherapies in the prevention and/or treatment of infectious diseases. She has expertise in immunology and vaccinology as well as in biological manufacturing including regulatory and industrial processes.
She worked for twelve years at Sanofi Pasteur at a global level and eighteen years in the Animal Health Pharmaceutical Industry (Merial, Schering-Plough, Boehringer Ingelheim). She has led the development and implementation of global product strategies, through defining priorities for Research & Development, Industrial Operations and various Business Units. This also involved the management of specific taskforces to optimize profitability, global forecast assessment of blockbusters, as well as business development opportunities for these Business Units.
From 2015 to 2017, she was the Head of the Pet Vaccines Business Unit at Merial/Boehringer Ingelheim Animal Health.
While supporting Biointelect in the E.U. being based in Lyon France, Isabelle also mentors start-up companies, supporting them in assessing market entry strategies and go-to-market activities.
Dr. Lyndon Raftery
Dr. Lyndon Raftery holds a first-class honours degree in Microbiology and Biochemistry, a PhD in Medical Biotechnology from the University of Queensland and an MBA specialising in entrepreneurial management from the Australian Institute of Business.
He has over five years research experience at the Australian Institute for Bioengineering and Nanotechnology (AIBN) ranging from biopharmaceutical antibody production to nanotechnology-based diagnostics. He has therapeutic area expertise in immuno-oncology and infectious disease and has co-authored multiple scientific manuscripts which are published in interdisciplinary journals.
Lyndon joined Biointelect in early 2018 as an Associate.
Dr. Danica Prodanovic
Dr. Danica Prodanovic holds a Master’s degree in Pharmacy from the University of Belgrade (Serbia) and a PhD in Pharmacology from the University of Melbourne (Australia).
Danica’s areas of expertise include pharmacology, allergic airway diseases, pharmaceutical technology, cosmetology and drug development. Her research experience extends from pharmaceutical formulation and bioengineering techniques to laboratory experimental design (in vitro/in vivo studies), gene silencing techniques and cell-based models of airway diseases.
Danica is a lead author and a co-author of multiple scientific publications.
Following a 4-month internship with Biointelect as an ‘APR Intern’ alumna, Danica officially joined Biointelect as an Associate in August 2018.
Emily Herz joined Biointelect in 2018 as administrative assistant. Emily has 4 years part-time experience as a pharmacy retail assistant in pharmacy, where she was responsible for customer service, managing stock and merchandising displays. She has developed a strong customer service mind-set and a good working knowledge of community pharmacy. She hopes to bring these organisational skills and health care sector knowledge to support both internal and external customers. She is passionate about small business and helping to develop the administrative, finance and marketing functions at Biointelect. Emily speaks French fluently, has creative flair and also freelances as a qualified makeup artist.
Claire Tobin Mercier
Claire Tobin Mercier established Claitom Consulting SARL in 2012 to fill the gap existing between AngloSaxon medical diagnostic and medical device companies and the French market. Claire has over 20 years business experience in the European market, primarily in France, as Claire created the French subsidiary of an Irish medical diagnostics company and managed that business from 1994-2009. With responsibility for sales, marketing, human resources and financial reporting, Claire brought the business to market leadership position in a highly competitive market.
In 2010-2011 Claire worked as an independent consultant based in Ireland and had contracts with EKF Diagnostics,Cardiff ; Trinity Biotech, Dublin and Qualigen Inc, USA. On moving back to France in 2012, she continued offering her consulting services with the creation of Claitom Consulting and has built up experience and knowledge of the following therapeutic areas : diagnostics in virology ; parasitology ; biomarkers in transplantation ; Point of Care diagnostics in diabetes and also the treatment of urinary incontinence globally. Development of commercial strategic plans for the introduction of these devices and diagnostics along with market studies are typically the type of contracts which I work on. The following companies have been or continue to be clients of mine : Trinity Biotech Ltd, Ireland ; EKF Diagnostics Ltd, UK ; Analytica Medical Ltd, AUS ; Qualigen Inc, USA ; MM France, Enterprise Ireland, France ; Biomedical Research (BMR) , Ireland and Novartis Pharma, France.
Carlos Espinal has long-term experience in tropical diseases, epidemiology, vaccinology and public health. One year (October 2015-16) as the Director of the Global Health Consortium, College of Public Health, Florida International University, Miami, Florida. One year as the Scientific Adviser of the Americas Health Foundation, USA. Over 20 years of experience in the vaccine pharmaceutical sector(Biolhener, GSK, Sanofi pasteur) as country, sub-regional and Regional Medical and Public Health Director.
Pierre Marin has over seventeen years of management experience in the Pharma industry from finance to strategy, operations and General Management at local, regional and global levels.
In his last management role, he was heading Sanofi Vaccines Business in Asia based in Singapore before becoming personal advisor to the newly appointed Sanofi Vaccines CEO for 2 years. Whilst in Asia, Pierre had full P&L responsibility for 15 countries. 350+ people and 150ME sales.
He brings four years’ experience as an independent consultant in the field of strategy definition and execution, operational turnaround, change management and executive coaching. His current clients include big pharma, biotech’s, investors & NGOs for whom he’s been leading. He also has experience dealing with companywide business cases from strategic framing to workshops facilitation to financial modeling to Board Level presentation and recommendations, business opportunities assessments from ground work to strategic recommendations along with Execution strategies for key projects such as new product launches, M&A, integration.
Pierre graduated from HEC Management School in Paris. He is an alumni of INSEAD and became and ICF certified coach in 2011 (RCS, London).
Pierre joined Biointelect in 2017 to establish their European office and is based in Lyon, France.
Ross Linsley is a proven leader, facilitator and strategist with 25+ years’ experience and expertise in the Pharmaceutical Industry and Public and Private Healthcare across the Asia Pacific Region. He also has broad experience covering Key Account Management, Commercial Excellence, Marketing, Sales and Business Development at a senior level with companies including Abbvie, Abbott, Merck Serono, AstraZeneca and Aventis.
Ross was Area Commercial Director for Japan and Asia Pacific (JAPAC) for the hepatitis C franchise where he was responsible for developing commercial strategy, defining the long range focus and alignment with the affiliates. Ross therefore brings an existing network in infectious diseases and insight to optimize private market strategy for the JAPAC region.
He is an innovative, culturally sensitive and collaborative consultant, whose approach is in building a better understand of the environment, risks and opportunities; and to develop clear strategies to improve business performance. Ross is joining the Biointelect team to help develop their Asia Pacific business.
Director, Graythan Regulatory Services
Mark Reid is a specialist in regulatory affairs and holds an MBA from Australian Graduate School of Management and a Master’s in Medical Science in Drug Development. He has more than eighteen years of clinical trial and drug development experience with new chemical entities, drug/device combinations and vaccines.
Mark is also a certified member (by examination) of the Regulatory Affairs Professionals Society for Canadian, European and the USA.
Mark is CEO of a biotechnology company and has been a board member for two not-for-profit companies while also consulting for two biotechnology companies as part of their Scientific Advisory Committees.
He has access to a wide range of consultants, having setup consultancy operations in the US, Europe and Australia. These experts include ex-regulators, regulatory consultants in SE Asia, CMC experts, auditors, organic chemists, toxicologists and medical doctors.